Cogstate invited shareholders, analysts, and the broader investment community to its inaugural Shareholder Day in Melbourne on 7th November 2025, which offered an opportunity for participants to engage directly with Cogstate’s global leadership team, hear from customers and its valued partner, Medidata, and gain unique insights into how Cogstate acted as a digital disruptor in Central Nervous System (CNS) disease clinical trials. The immersive event highlighted how Cogstate’s advanced technology and data solutions redefined the measurement of brain health, accelerated therapeutic development, and shaped the future of Alzheimer’s and other CNS disease research. The program featured company and guest presentations alongside Cogstate’s Experiential Lab, a showcase of the company’s technology, CNS disease focus, and operating segments hosted by Cogstate’s subject matter experts.
https://investors.cogstate.com/shareholder-day